[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-361165-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-361165-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","structure-based-screening-and-identification-of-a-novel-auroraa-targeting-peptide-with-antiproliferative-activity-against-prostate-cancer-cells","Structure-based screening and identification of a novel AuroraA-targeting peptide with antiproliferative activity against prostate cancer cells","","Aurora-A is a potential therapeutic target in prostate cancer. This study used virtual screening to identify four Aurora-A-targeting peptides, with Peptide-1 showing the most favorable profile. Molecular docking and Mst assays indicated the lowest predicted binding free energy and strongest Aurora-A binding affinity (Kd = 0.72 ± 0.04 μM). MD simulation, MM/PBSA, and free-energy landscape analyses supported conformational stability driven mainly by electrostatic interactions.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/structure-based-screening-and-identification-of-a-novel-auroraa-targeting-peptide-with-antiproliferative-activity-against-prostate-cancer-cells/361165/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/structure-based-screening-and-identification-of-a-novel-auroraa-targeting-peptide-with-antiproliferative-activity-against-prostate-cancer-cells/361165.png","ImageObject",300,407,{"name":42,"@type":43},"PakDamar76","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-19","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What method identified the Aurora-A-targeting peptides in this study?","Question",{"text":63,"@type":64},"Virtual screening identified four Aurora-A-targeting peptides, and Peptide-1 showed the most favorable overall profile.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was Peptide-1 evaluated for binding to Aurora-A?",{"text":68,"@type":64},"Molecular docking and Mst assays assessed binding, showing Peptide-1 had the lowest predicted binding free energy and the strongest binding affinity (Kd = 0.72 ± 0.04 μM).",{"name":70,"@type":61,"acceptedAnswer":71},"What evidence supports Aurora-A as the target for Peptide-1’s antiproliferative effect?",{"text":72,"@type":64},"Aurora-A knockdown reduced cellular sensitivity to Peptide-1, indicating target-dependent activity in prostate cancer cells.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},361165,1790168038,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090893057,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Journal of EnzymE InhIbItIon and mEdIcInal chEmIstry 2026, Vol. 41, no. 1, 2700842  \n[https://doi.org/10.1080/14756366.2026.2700842](https://doi.org/10.1080/14756366.2026.2700842)  \nReseaRch aRticle    \nStructure-based screening and identification of a novel AuroraA-targeting peptide with antiproliferative activity against prostate cancer cells  \nBei-Bei huanga†, haijing Jianga†, Yaozhi hub†, Jia-Jia Gea and Xiaohao liub  \nadrug clinical trial facility office, the affiliated hospital of Xuzhou medical university, Xuzhou, china; bdepartment of Pharmaceutical analysis, china Pharmaceutical university, nanjing, china  \nABSTRACT  \naurora-a is a potential therapeutic target in prostate [cancer. in](cancer. in) this study, virtual screening identified four aurora-a-targeting peptides, among which Peptide-1 showed the most favourable profile. Molecular docking and Mst assays demonstrated that Peptide-1 had the lowest predicted binding free energy and the strongest binding affinity towards aurora-a (Kd = 0.72 ± 0.04 μM). MD simulation, MM/PBsa, and free-energy landscape analyses indicated that the aurora-a–Peptide-1 complex was conformationally stable and mainly driven by electrostatic interactions. Mtt assays showed that Peptide-1 inhibited the proliferation of Pc3, DU145, and Nci-h660 cells, with weaker activity in RWPe-1 cells. aurora-a knockdown reduced cellular sensitivity to Peptide-1, supporting its target-dependent activity. qRt-PcR further showed increased p53 and p21 mRNa expression after Peptide-1 treatment in Pc3/p53Wt cells. these findings suggest that Peptide-1 may act as an aurora-a-targeting peptide with antiproliferative activity in prostate cancer cells.  \nIntroduction  \nARTICLE HISTORY  \nReceived 2 May 2026 Revised 12 June 2026 accepted 4 July 2026  \nKEYWORDS  \nantiproliferative activity; aurora-a; peptide; prostate cancer; virtual screening  \nProstate cancer represents a major malignancy in the male population and is projected to account for 30% of all newly diagnosed cancers in males in 2025, ranking second among causes of cancer-related mortality in men1,2. current clinical management is largely based on the dependence of prostate cancer on androgen receptor (aR) signalling and involves inhibition of aR activity through antiandrogen therapy and androgen deprivation therapy (aDt)3. although second-generation aR-targeted agents, such as enzalutamide and abiraterone, have provided clinical benefit for some patients4–6, the development of therapeutic resistance remains a major factor limiting their long-term efficacy and further improvement in patient outcomes7. therefore, the exploration of new therapeutic targets and intervention strategies remains necessary for the treatment of prostate cancer.  \naurora kinase a (aurora-a) is encoded by the aURKa gene and is a serine/threonine kinase belonging to the aurora kinase family, which also includes aurora-B and [aurora-c](aurora-c8 . it)[8](aurora-c8 . it)[ . it](aurora-c8 . it) consists of 403 amino acids and has a predicted molecular weight of 45.8 kDa9. structurally, aurora-a contains a central catalytic kinase domain of 251 amino acids, flanked by a noncatalytic N-terminal region of 132 amino acids anda short c-terminal tail of 20 amino acids, and plays an important role in centrosome maturation, spindle assembly, and regulation of mitotic progression9–11. Overexpression of aurora-a can induce genomic instability and neoplastic transformation, suggesting that it may have oncogene-like properties12. in addition, aurora-a is frequently overexpressed and amplified in multiple tumour types, including breast,  \nCONTACT bei-bei huang  [bei_huang1993@163.com](bei_huang1993@163.com)  drug clinical trial facility office, the affiliated hospital of Xuzhou medical university, Xuzhou, 221000, china.  \n supplemental data for this article can be accessed online at [https://doi.org/10.1080/14756366.2026.2700842](https://doi.org/10.1080/14756366.2026.2700842) .  \n†these authors cont","cbCair0jy3Fmmv63","https://ap.wps.com/l/cbCair0jy3Fmmv63","pdf",1746741,18,"English","# Abstract\n# Introduction\n# Article information\n## Received, revised, accepted\n## Keywords\n# Results and discussion","[{\"question\":\"What method identified the Aurora-A-targeting peptides in this study?\",\"answer\":\"Virtual screening identified four Aurora-A-targeting peptides, and Peptide-1 showed the most favorable overall profile.\"},{\"question\":\"How was Peptide-1 evaluated for binding to Aurora-A?\",\"answer\":\"Molecular docking and Mst assays assessed binding, showing Peptide-1 had the lowest predicted binding free energy and the strongest binding affinity (Kd = 0.72 ± 0.04 μM).\"},{\"question\":\"What evidence supports Aurora-A as the target for Peptide-1’s antiproliferative effect?\",\"answer\":\"Aurora-A knockdown reduced cellular sensitivity to Peptide-1, indicating target-dependent activity in prostate cancer cells.\"}]","Structure-based screening and identification of a novel AuroraA-targeting peptide with antiproliferative activity against prostate cancer cells | PDF",1790143371,45,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a90a305f283ee2dfb99ff6f520f66dbf.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ddd29d989a00b72571c820fd8313a625.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/70d97a334fa6ce58eaf02cd5bf57baeb.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9557a39288b1e5c9204c4372dccf3ad9.webp",980,1306]